- Home
- MDGL vs BBIO Comparison
MDGL vs BBIO Comparison
Compare MDGL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- BBIO
- Stock Information
- Founded
- MDGL 2011
- BBIO 2015
- Country
- MDGL United States
- BBIO United States
- Employees
- MDGL N/A
- BBIO N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MDGL Health Care
- BBIO Health Care
- Exchange
- MDGL Nasdaq
- BBIO Nasdaq
- Market Cap
- MDGL 6.1B
- BBIO 8.0B
- IPO Year
- MDGL N/A
- BBIO 2019
- Fundamental
- Price
- MDGL $304.86
- BBIO $45.12
- Analyst Decision
- MDGL Strong Buy
- BBIO Strong Buy
- Analyst Count
- MDGL 9
- BBIO 14
- Target Price
- MDGL $420.63
- BBIO $58.85
- AVG Volume (30 Days)
- MDGL 305.4K
- BBIO 3.3M
- Earning Date
- MDGL 08-06-2025
- BBIO 07-31-2025
- Dividend Yield
- MDGL N/A
- BBIO N/A
- EPS Growth
- MDGL N/A
- BBIO N/A
- EPS
- MDGL N/A
- BBIO N/A
- Revenue
- MDGL $317,383,000.00
- BBIO $127,415,000.00
- Revenue This Year
- MDGL $286.17
- BBIO $102.05
- Revenue Next Year
- MDGL $64.17
- BBIO $54.69
- P/E Ratio
- MDGL N/A
- BBIO N/A
- Revenue Growth
- MDGL N/A
- BBIO N/A
- 52 Week Low
- MDGL $200.63
- BBIO $21.72
- 52 Week High
- MDGL $377.46
- BBIO $45.48
- Technical
- Relative Strength Index (RSI)
- MDGL 61.70
- BBIO 77.53
- Support Level
- MDGL $277.64
- BBIO $39.65
- Resistance Level
- MDGL $314.22
- BBIO $45.18
- Average True Range (ATR)
- MDGL 11.62
- BBIO 1.49
- MACD
- MDGL 3.11
- BBIO 0.54
- Stochastic Oscillator
- MDGL 82.64
- BBIO 99.13
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.